J Lauschke1, M Busch2, W Haverkamp3, A Bulava4, R Schneider5, D Andresen6, H Nägele7, C Israel8, G Hindricks9, D Bänsch5. 1. Department of Electrophysiology, KMG Hospital Güstrow, Friedrich-Trendelenburg-Allee 1, 18273, Güstrow, Germany. Lauschke.mail@freenet.de. 2. Department of Cardiology, University Hospital, Greifswald, Germany. 3. Department of Cardiology, Charité University Hospital, Berlin, Germany. 4. Faculty of Health and Social Sciences, University of South Bohemia, České Budejovice, Czech Republic. 5. Department of Electrophysiology, KMG Hospital Güstrow, Friedrich-Trendelenburg-Allee 1, 18273, Güstrow, Germany. 6. Evangelical Hospital Hubertus, Berlin, Germany. 7. Department of Heart Failure and Devices, Albertinen Hospital, Hamburg, Germany. 8. Evangelical Hospital, Bielefeld, Germany. 9. Heart Centre Leipzig, University Hospital, Leipzig, Germany.
Abstract
BACKGROUND: A new implantable cardiac monitor (BioMonitor, Biotronik) with a continuous remote monitoring option was prospectively implanted in patients with suspected arrhythmias or for therapy control after atrial fibrillation (AF) ablation. A three-lead ECG detection was intended to make the implantation more independent of the implantation site and the electrical heart axis. Because noise is a frequent problem in implantable cardiac monitors, an active noise detection algorithm was implemented. The aim of the trial was to evaluate the clinical performance of the device. METHODS: The device performance was evaluated in a prospective nonrandomized multicenter study with a follow-up of 12 months. Study endpoints were device-related serious adverse events at 3 months, appropriate QRS detection in direct comparison with synchronized Holter ECG recordings, sensitivity and positive predictive value of arrhythmia detection in comparison with Holter ECG and independent of it, and noise burden during the entire follow-up period. RESULTS: The implantation was successful in all 152 patients. Two device-related serious adverse events (pocket infections) occurred by 3 months. The mean QRS amplitude of 0.3 ± 0.2 mV at implantation remained stable over 12 months. QRS sensing performance indicated little over- and undersensing in most patients. More than 80 % of the patients had more than 22 h of noise-free monitoring per day. CONCLUSION: BioMonitor effectively detects patients with bradycardia, tachycardia, AF, or asystole. Active noise detection seems to reduce the transmission of meaningless data without diminishing the positive predictive value of the device.
BACKGROUND: A new implantable cardiac monitor (BioMonitor, Biotronik) with a continuous remote monitoring option was prospectively implanted in patients with suspected arrhythmias or for therapy control after atrial fibrillation (AF) ablation. A three-lead ECG detection was intended to make the implantation more independent of the implantation site and the electrical heart axis. Because noise is a frequent problem in implantable cardiac monitors, an active noise detection algorithm was implemented. The aim of the trial was to evaluate the clinical performance of the device. METHODS: The device performance was evaluated in a prospective nonrandomized multicenter study with a follow-up of 12 months. Study endpoints were device-related serious adverse events at 3 months, appropriate QRS detection in direct comparison with synchronized Holter ECG recordings, sensitivity and positive predictive value of arrhythmia detection in comparison with Holter ECG and independent of it, and noise burden during the entire follow-up period. RESULTS: The implantation was successful in all 152 patients. Two device-related serious adverse events (pocket infections) occurred by 3 months. The mean QRS amplitude of 0.3 ± 0.2 mV at implantation remained stable over 12 months. QRS sensing performance indicated little over- and undersensing in most patients. More than 80 % of the patients had more than 22 h of noise-free monitoring per day. CONCLUSION: BioMonitor effectively detects patients with bradycardia, tachycardia, AF, or asystole. Active noise detection seems to reduce the transmission of meaningless data without diminishing the positive predictive value of the device.
Entities:
Keywords:
Artifacts; Atrial fibrillation; Cardiac arrhythmia; Electrocardiography; Predictive value
Authors: Michele Brignole; Panos Vardas; Ellen Hoffman; Heikki Huikuri; Angel Moya; Renato Ricci; Neil Sulke; Wouter Wieling; Angelo Auricchio; Gregory Y H Lip; Jesus Almendral; Paulus Kirchhof; Etienne Aliot; Maurizio Gasparini; Frieder Braunschweig; Gregory Y H Lip; Jesus Almendral; Paulus Kirchhof; Gian Luca Botto Journal: Europace Date: 2009-05 Impact factor: 5.214
Authors: Rukshen Weerasooriya; Paul Khairy; Jean Litalien; Laurent Macle; Meleze Hocini; Frederic Sacher; Nicolas Lellouche; Sebastien Knecht; Matthew Wright; Isabelle Nault; Shinsuke Miyazaki; Christophe Scavee; Jacques Clementy; Michel Haissaguerre; Pierre Jais Journal: J Am Coll Cardiol Date: 2011-01-11 Impact factor: 24.094
Authors: Matthew Swale; Sinny Delacroix; Glenn Young; Vincent Paul; Luke McSpadden; Kyungmoo Ryu; David Di Fiore; Maria Santos; Isabel Tan; Andre Conradie; MyNgan Duong; Nisha Schwarz; Stephen Worthley; Stephen Pavia Journal: Cardiovasc Digit Health J Date: 2021-12-30